The Role of Serum Fructosamine as a Monitoring Tool in Gestational Diabetes Mellitus Treatment in Vietnam — ASN Events

The Role of Serum Fructosamine as a Monitoring Tool in Gestational Diabetes Mellitus Treatment in Vietnam (#296)

Truong H Le 1 , Ngoc M To 2 , Chi V Le 3 , Luu T Cao 2
  1. Cho Ray Hospital, Ho Chi Minh, HO CHI MINH, Viet Nam
  2. Project Developement, Leafshield Group, Ho Chi Minh, Vietnam
  3. Hue University of Medical, Hue

Introduction: Gestational diabetes mellitus (GDM) requires continuos glucose monitoring at least every two weeks and therefore an alternative marker of glycemia for short-term control is considering a potential tool for the healthcare providers. There are published studies have indicated that the glycosylated serum protein is a better indicator than glycosylated hemoglobin in GDM monitoring. Based on the actual practice in Vietnam, this study was designed to evaluate the role of serum fructosamine as a monitoring tool in GDM treament and its correlations with fasting blood glucose (G0), 2-hour postprandial glucose (G2) and glycosylated hemoglobin (HbA1c).

Methods: A total of 500 pregnant women diagnosed with GDM by the 75-gram oralglucose tolerance test at Endocrinology Department, Cho Ray hospital, Vietnam from June 2014 to March 2015 received a continuos glucose monitoring method which consists of bi-weekly on-site visit every 2 weeks with glycosylated serum protein test, fasting blood glucose test and 2-hour postprandial glucose test; HbA1c test for every 3 months; and nutritious consultance for daily diet program. The subjects still received routine treatment at the hospital, with tight follow-up from their healthcare providers.

Results: Serum fructosamine level was found to have a light correlation with G0 (r=0.3458, p<0.001) and HbA1c (r=0.3544, p<0.001), and moderately correlated with G2 (r=0.4379, p<0.001). During study timeline, the delivery outcome of 287 women were recorded with the average age of 38.5 ± 1.5 weeks, 9% of them have macrosomia, 2.8% have premature birth before week 35th and 9.8% have premature birth before week 37th; 64.8% of cesarean section and none of them have perinatal or neonatal mortality. The study provides a reference interval of serum fructosamine for GDM patient was 112.9 ± 20.7 μmol/dL.

Conclusion: The present results suggests that serum fructosamine is as effective as HbA1c as a reflection of blood glucose control in GDM patient, with a positive result in delivery outcome (0% perinatal or neonatal mortality). The reference value of serum fructosamine measurement provided a potential monitoring utility in GDM treatment for hospitals in Vietnam.